Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology

Journal article
(Letter)


Publication Details

Author(s): Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, Mcarthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A
Journal: European journal of cancer
Publication year: 2019
Volume: 112
Pages range: 29-31
ISSN: 0959-8049


FAU Authors / FAU Editors

Heinzerling, Lucie Prof. Dr.
Hautklinik


External institutions with authors

Aix-Marseille University / Aix-Marseille Université
Fondazione IRCCS: Istituto Nazionale dei Tumori
Institut Gustave-Roussy
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
National and Kapodistrian University of Athens
Peter MacCallum Cancer Centre
Universitätsklinikum Essen
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsspital Zürich (USZ)
Université Sorbonne Paris Cité
University of California Los Angeles (UCLA)
University of Sydney
Vanderbilt University


How to cite

APA:
Heinzerling, L., Ascierto, P.A., Dummer, R., Gogas, H., Grob, J.-J., Lebbe, C.,... Hauschild, A. (2019). Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology. European journal of cancer, 112, 29-31. https://dx.doi.org/10.1016/j.ejca.2019.01.015

MLA:
Heinzerling, Lucie, et al. "Adverse events 2.0-Let us get SERIOs New reporting for adverse event outcomes needed in the era of immunooncology." European journal of cancer 112 (2019): 29-31.

BibTeX: 

Last updated on 2019-23-05 at 00:08